Inventor · disambiguated record
Alan Edward Royce
Also filed as: ROYCE ALAN E · ROYCE ALAN EDWARD
9 granted patents·29 pending applications·697 citations·filing 1985–2023
90Inventor score
Top patents by PatentIndex Score
38 records- 0196US5273758ADirectly compressible polyethylene oxide vehicle for preparing therapeutic dosage formsSANDOZ LTD·Filed 1992·Granted Dec 28, 1993·311 cites·26 claims
- 0292US5403593AMelt granulated compositions for preparing sustained release dosage formsSANDOZ LTD·Filed 1992·Granted Apr 4, 1995·156 cites·23 claims
- 0391US4723958APulsatile drug delivery systemMERCK & CO INC·Filed 1986·Granted Feb 9, 1988·179 cites·20 claims
- 0483US8475839B2Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the sameCAO YU·Filed 2012·Granted Jul 2, 2013·7 cites·7 claims
- 0581US8324283B2Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcoholOOMURA TOMOYUKI·Filed 2008·Granted Dec 4, 2012·9 cites·32 claims
- 0675US4690775AEmulsion-based gel and process for preparing sameRESEARCH CORP·Filed 1985·Granted Sep 1, 1987·31 cites·32 claims
- 0775US2022031609A1Organic compoundsNOVARTIS AG·Filed 2021·Application pending·0 cites
- 0873US8435946B2Orally dosed pharmaceutical compositions comprising a delivery agent in micronized formLI SHOUFENG·Filed 2008·Granted May 7, 2013·2 cites·12 claims
- 0972US8748383B2Method for treating bone related diseases and calcium disordersLI SHOUFENG·Filed 2013·Granted Jun 10, 2014·2 cites·10 claims
- 1070US2024115536A1Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitorNOVARTIS AG·Filed 2023·Application pending·0 cites
- 1168US2020237690A1Organic compoundsNOVARTIS AG·Filed 2020·Application pending·0 cites
- 1265US2019175527A1Organic compoundsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1361US2017290787A1Organic CompoundsNOVARTIS AG·Filed 2017·Application pending·0 cites
- 1460US2021085631A1Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitorNOVARTIS AG·Filed 2020·Application pending·0 cites
- 1559US2009203798A1Solid Pharmaceutical Compositions Comprising a SIP Receptor Agonist and a Sugar AlcoholOOMURA TOMOYUKI·Filed 2008·Application pending·0 cites
- 1658US2014255497A1Organic CompoundsOOMURA TOMOYUKI·Filed 2014·Application pending·0 cites
- 1758US2013108675A1Organic compoundsNOVARTIS AG·Filed 2012·Application pending·0 cites
- 1856US2014011885A1Organic CompoundsOOMURA TOMOYUKI·Filed 2013·Application pending·0 cites
- 1953US2010267786A1Dual acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and ne utral endopeptidase (ep) inhibitorAL-FAYOUMI SULIMAN·Filed 2008·Application pending·0 cites
- 2053US2010003321A1Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the sameCAO YU·Filed 2007·Application pending·0 cites
- 2153US2008255048A1Pharmaceutical CompositionAZRIA MOISE·Filed 2006·Application pending·0 cites
- 2253US2008287412A1Therapeutic combination of amlodipine and benazepril/benazeprilatCOMFORT ANN R·Filed 2008·Application pending·0 cites
- 2351US2007065505A1Orally dosed pharmaceutical compositions comprising a delivery agent in micronized formLI SHOUFENG·Filed 2004·Application pending·0 cites
- 2450US9622975B2Pharmaceutical compositionNOVARTIS AG·Filed 2015·Granted Apr 18, 2017·0 cites·8 claims
- 2550US2011105620A1Organic compoundsOOMURA TOMOYUKI·Filed 2011·Application pending·0 cites
- 2650US2006275357A1Organic compoundsOOMURA TOMOYUKI·Filed 2004·Application pending·0 cites
- 2749US2008064760A1Spontaneously Dispersible Pharmaceutical CompositionLI PING·Filed 2005·Application pending·0 cites
- 2847US2014287040A1FormulationJOSHI YATINDRA·Filed 2014·Application pending·0 cites
- 2947US2011218148A1Pharmaceutical compositionAZRIA MOISE·Filed 2011·Application pending·0 cites
- 3046US2007134319A1Pharmaceutical formulations of bisphosphonatesNOVARTIS AG·Filed 2004·Application pending·0 cites
- 3145US2021169854A13'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulationNOVARTIS AG·Filed 2020·Application pending·0 cites
- 3245US2010196467A1Therapeutic combination of amlodipine and benazepril/benazeprilatDALEY WILLIAM LIONEL·Filed 2010·Application pending·0 cites
- 3345US2008227825A1FormulationJOSHI YATINDRA·Filed 2006·Application pending·0 cites
- 3443US2013052239A1FormulationJOSHI YATINDRA·Filed 2012·Application pending·0 cites
- 3541US2010035949A1Microemulsion dosage forms of valsartan and methods of making the sameJOSHI YATINDRA·Filed 2007·Application pending·0 cites
- 3640US2004062787A1Therapeutic combination of amlodipineand benazepril/benazeprilatFiled 2001·Application pending·0 cites
- 3739US2011045062A1FormulationJOSHI YATINDRA·Filed 2010·Application pending·0 cites
- 3837US2010233253A1Extended release gastro-retentive oral drug delivery system for valsartanNOVARTIS AG·Filed 2007·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Alan Edward Royce files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →